AI Article Synopsis
- - Psoriasis is a long-term inflammatory skin condition influenced by both genetics and environmental factors, and some patients may need systemic treatment with immunobiological agents, which can have side effects.
- - A specific case of a 58-year-old patient treated with adalimumab for psoriasis over five years showed signs of interstitial pneumonia.
- - The patient's lung issues improved significantly after stopping adalimumab, highlighting the need for more awareness about potential late pulmonary side effects from anti-TNF treatments used for psoriasis.
Article Abstract
Psoriasis is a chronic inflammatory disease that affects the skin variably, according to genetic and environmental factors. Some patients may benefit from systemic treatment with immunobiological agents, drugs that can be accompanied by several adverse effects. A case of a 58-year-old patient undergoing treatment for psoriasis with adalimumab for five years is reported. Alterations compatible with interstitial pneumonia were detected with important regression after adalimumab discontinuation. This case is relevant due to the scarcity of reports on late pulmonary adverse effect of anti-TNF treatment of psoriasis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8245706 | PMC |
| http://dx.doi.org/10.1016/j.abd.2020.08.016 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Excimer light versus topical methotrexate 1% hydrogel in treatment of scalp psoriasis: clinical and dermoscopic study.
Arch Dermatol Res
January 2025
Dermatology and Venereology Department, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.
One of the most frequently impacted locations by psoriasis is the scalp. It is seen in about 80% of psoriasis cases worldwide, and its treatment is challenging. To compare the efficacy and safety of excimer light versus topical methotrexate (MTX) 1% hydrogel in treatment of scalp psoriasis.
View Article and Find Full Text PDFImpact of topical and systemic therapy on carotid-intima media thickness in psoriasis.
Arch Dermatol Res
January 2025
Cerrahpasa Faculty of Medicine, Department of Dermatology, Istanbul University-Cerrahpasa, Istanbul, Turkey.
Atherosclerosis, in which chronic inflammation is also effective in it's pathogenesis, is an important cause of morbidity and mortality in psoriasis patients. Early diagnosis and management of atherosclerosis is important. Measurement of carotid intima media thickness is a method used to determine subclinical atherosclerosis.
View Article and Find Full Text PDFComparative activity of dimethyl fumarate derivative IDMF in three models relevant to multiple sclerosis and psoriasis.
FEBS Open Bio
January 2025
Sunny BioDiscovery Inc., Santa Paula, CA, USA.
Dimethyl fumarate (DMF) is an anti-inflammatory and immunoregulatory medication used to treat multiple sclerosis (MS) and psoriasis. Its skin sensitization property precludes its topical use, which is unfortunate for the treatment of psoriasis. Isosorbide di-(methyl fumarate) (IDMF), a novel derivative of DMF, was synthesized to circumvent this adverse reaction and unlock the potential of topical delivery, which could be useful for treating psoriasis in the subpopulation of psoriatic MS patients, as well as in the general population.
View Article and Find Full Text PDFA real-world Pharmacovigilance study of brodalumab based on the FDA adverse event reporting system.
Sci Rep
January 2025
Department of Dermatology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.
Brodalumab, a humanized monoclonal antibody that targets the interleukin-17 receptor A, is primarily used to manage moderate-to-severe plaque psoriasis. Although it has demonstrated favorable efficacy and safety in clinical trials, the strict inclusion and exclusion criteria may not fully reflect its safety profile in real-world settings. As its use becomes more widespread in clinical practice, understanding its safety in real-world applications is crucial.
View Article and Find Full Text PDFTwo rashes, one patient: Enfortumab vedotin-induced interface dermatitis and pembrolizumab-induced psoriatic disease treated with ixekizumab.
JAAD Case Rep
November 2024
Department of Dermatology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!